Back

Angiotensin receptor-1 antagonists improve endothelial glycocalyx and aortic stiffness after 2 years successful treatment in untreated patients with essential hypertension

29 August 2016 (15:49 - 15:56)
Organised by:
Congress Presentation Part of: Complications of hypertension Treatment of hypertension ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Helen Triantafyllidi

Attikon University Hospital, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Low testosterone and high C-reactive protein are complementary determinants of global arterial function and early structural changes in men with arterial hypertension
Doctor N. Ioakeimidis (Athens, GR)
Abstract Slides
Presentation thumbnail
Longitudinal changes of the serum calcium levels and accelerated progression of arterial stiffness with age.
Doctor K. Kimura (Tokyo, JP)
Abstract Slides
Presentation thumbnail
Evaluation of coronary flow velocity by Doppler echocardiography in the treatment of hypertension with the ACEi/ARB: correlation to the histological cardiac fibrosis
Doctor C. Wei-Ting (Tainan, TW)
Abstract Slides
Presentation thumbnail
Testosterone loss as essential parameter of silent target organ damage in primary hypertension
Doctor A. Angelis (Athens, GR)
Abstract Slides
Presentation thumbnail
Correlation between cognitive decline and blood pressure in elderly patients with controlled hypertension
Mr A. Noriega de la Colina (Montreal, CA)
Abstract Slides

Access the full session

Session thumbnail
Complications of hypertension

The Event

Event poster

ESC Congress 2016

29 August 2016 15:49 CET
You may be interested in
thumbnail
Congress Presentation
Endothelial glycocalyx improvement after six months and one-year of antiretroviral therapy in treatment naive patients with human immunodeficiency virus
26 August 2022
thumbnail
Congress Presentation
Correlation between arterial stiffness and altered lusitropy in essential hypertension
29 June 2021
thumbnail
Congress Session
Arterial hypertension
30 August 2024
thumbnail
Congress Presentation
Empagliflozin treatment does not affect the hypertensive response to Ang II administration to rats but decreases oxidative stress in the arterial wall, and endothelial and cardiac dysfunction
1 September 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources